Good news!
If your cancer is Triple Negative (TNBC) and you’ve already had two or more therapies for metastatic disease, then you’re eligible to receive the newly-approved drug Trodelvy (Sacituzumab Govitecan – formerly IMMU-132).
Trodelvy, which is administered intravenously, consists of the chemotherapy drug irinotecan linked with an antibody targeted against TROP-2, a cell-surface protein that is expressed in more than 90% of TNBC. FDA approval was based upon a Phase 1/2 trial of 108 TNBC MBC patients who had previously undergone a median of three prior lines of therapy (80% of whom had visceral metastases). The results of the study determined that the median Progression-Free Survival (PFS) was 5.5 months and the median Overall Survival (OS) was 13.0 months. From: oncnursingnews.com/web-excl...
The above and similar information about approved MBC treatments and cutting edge research is in my book, “The Insider’s Guide to Metastatic Breast Cancer” which is also available as a complimentary .pdf. For information, please visit insidersguidembc.com/about
Association Between HER2 Expression and Prognosis in Metastatic TNBC
